Breast Conservation Surgery vs Mastectomy: What Surgeons Recommend Today

Breast cancer treatment has evolved significantly over the past few decades, moving from radical removal approaches to more personalized and tissue-preserving techniques. Today, surgeons no longer view breast conservation surgery (BCS) and mastectomy as competing options, but as equally effective strategies chosen based on individual patient needs.

With the growing availability of reconstructive surgery in Kolkata, patients now also have better cosmetic and psychological outcomes regardless of the surgical path they choose.

Understanding The Two Surgical Options

When faced with a breast cancer diagnosis, understanding the available surgical options is crucial for making an informed decision. Each approach is designed to effectively treat the disease while considering the patient’s long-term health, comfort, and quality of life.

What Is Breast Conservation Surgery (BCS)?

Breast conservation surgery, or lumpectomy or partial mastectomy, is a procedure that involves the removal of the tumor and a small amount of surrounding healthy tissue while preserving most of the breast.

The main objective is to remove cancer without altering the natural shape and appearance of the breast. Radiation therapy is usually administered after surgery to kill any remaining cancer cells and minimize the chances of recurrence.

What Is A Mastectomy?

Mastectomy is the removal of the whole breast tissue, and in other cases, the lymph nodes and skin around the breast. It can be done on either breast or both breasts based on the type of cancer and risk factors.

After a mastectomy, patients can choose to have breast reconstruction with the help of modern surgical procedures, such as those provided in reconstructive surgery in Kolkatta, which can help to restore the shape and symmetry of the breast.

Major Differences Between BCS And Mastectomy

The basic distinction is the degree of tissue excision. BCS leaves the majority of the breast, but a mastectomy takes away all of it.

 

Factor	Breast Conservation Surgery (BCS)	Mastectomy
Extent of Surgery	Removes tumor with a small margin of healthy tissue	Removes entire breast tissue
Invasiveness	Less invasive	More extensive surgery
Cosmetic Outcome	Preserves most of the natural breast shape	The breast is removed (reconstruction may be needed)
Recovery Time	Generally faster recovery	Longer recovery period
Radiation Therapy	Usually required after surgery	May or may not be required
Risk of Recurrence	Slightly higher local recurrence risk	Lower local recurrence risk
Hospital Stay	Often shorter or a day-care procedure	May require a longer hospital stay
Suitability	Early-stage cancer, smaller tumors	Larger tumors, multiple areas, or high-risk cases
Impact on Body  mage	Better preservation of body image	May impact body image (can be improved with reconstruction)

Notably, several studies indicate that both methods have equal chances of survival in the long term in early-stage breast cancer.

Eligibility Criteria: Who Can Opt For What?

Not every patient is suited for the same surgical approach, as the choice largely depends on individual clinical factors. Tumor size, stage, location, and overall health all play a crucial role in determining eligibility. Understanding who can opt for which procedure helps ensure both effective treatment and optimal long-term outcomes.

Candidates for Breast Conservation Surgery

BCS is usually prescribed to patients with:

• Stage I or II breast cancer
• Tumors smaller than 5 cm
• One tumor in one area
• No radiation therapy contraindications
• Some cases do not have high-risk genetic mutations like BRCA

It might not apply to patients who have more than one tumor in other parts of the breast or those with advanced disease.

Candidates for Mastectomy

Mastectomy may be suggested when:

• The tumor is huge in comparison with the size of the breast
• It has several tumors in various quadrants
• Cancer is metastatic (Stage III or IV)
• The genetic risk of recurrence is high in the patient
• Radiation therapy is not an option or choice

Moreover, other patients might opt to undergo mastectomy to have a sense of security or to alleviate the fear of recurrence.

Advancements In Breast Surgery

The current surgical advances have greatly enhanced the results, particularly in patients who want to preserve their breasts.

Oncoplastic Surgery

Among the most remarkable developments is the oncoplastic breast surgery that involves the use of both cancer resection and plastic surgery. This enables the surgeons to excise bigger tumors without altering the shape and symmetry of the breast.

This has increased the eligibility of BCS so that more women can avoid mastectomy and still have safe control of cancer.

Improved Imaging and Targeting

Modern imaging techniques have assisted surgeons in accurately identifying tumors so that they can be fully removed without damaging normal tissue. This enhances cosmetic outcomes as well as oncological safety.

Advanced Reconstruction Methods

The emergence of reconstructive surgery in Kolkatta has given patients who have undergone mastectomy the opportunity to have an immediate or delayed reconstruction with the help of implants or autologous tissue.

Reconstruction has been brought to improve psychological well-being, body image, and quality of life.

Influencing Factors of Surgical Decision-Making

The decision to use BCS or mastectomy is not only a medical choice, but a very personal one, which depends on several factors:

1. Cancer Stage and Tumor Characteristics

The main determinants include tumor size, location, and spread. BCS is more appropriate in early-stage cancers, whereas mastectomy is usually necessary in advanced cases.

2. Survival and Recurrence Outcomes

It has always been demonstrated that the survival rates are the same with BCS (including radiation) and mastectomy in the case of early-stage cancers. Nevertheless, BCS can be slightly more likely to recur locally, which can be treated.

3. Patient Preference

A major role is played by emotional and psychological factors. There are those patients who want to keep their breasts, and others opt to undergo a mastectomy to have peace of mind. Studies show fear of recurrence is a major driver for choosing mastectomy.

4. Access to Radiation Therapy

Since BCS requires post-operative radiation, access to treatment facilities can influence the decision. Patients without easy access may opt for a mastectomy.

5. Cosmetic and Quality-of-Life Concerns

BCS tends to provide superior cosmetic results and satisfaction. Nevertheless, the modern methods of reconstruction have also helped to enhance the results of mastectomy patients considerably.

What Do Surgeons Recommend Today?

Modern breast surgeons support a multidisciplinary patient-centered approach. Instead of prescribing a single solution, they consider:

• Clinical (tumor size, stage, genetics)
• Access to care and patient lifestyle
• Motivational preparedness and individual interests

Surgeons are increasingly preferring breast conservation surgery in most of the early-stage cases because of its good results and quality-of-life advantages. Nevertheless, mastectomy is necessary in more complicated or risky cases.

Conclusion

The debate between breast conservation surgery and mastectomy is no longer about which is superior, but about which is most appropriate for the individual patient. Oncoplastic techniques and reconstructive surgery in Kolkata have advanced, and patients now have a choice of safer, more personalized, and cosmetically satisfying options.

 

 

This is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.   

https://gscrochetdesigns.blogspot.com. one can see my crochet creations  

https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes    

https://kneereplacement-stickclub.blogspot.com. for info on knee replacement

https://GSiyers home remedies.blogspot.com   is the latest addition to my blogs

 

New Treatments for Multiple Myeloma

Multiple myeloma is a complex blood cancer characterized by the proliferation of malignant plasma cells within the bone marrow. Recent advancements in treatment have significantly improved patient outcomes, introducing innovative therapies that target the disease more precisely and effectively.

Traditional Treatment Approaches 

 

Historically, multiple myeloma has been managed through a combination of therapies: 

 

Chemotherapy: Utilizes cytotoxic drugs to kill rapidly dividing cancer cells. 

 

Corticosteroids: Help reduce inflammation and directly combat myeloma cells. 

 

Stem Cell Transplantation: Particularly autologous stem cell transplants (ASCT), where a patient's own stem cells are used to restore bone marrow function after high-dose chemotherapy. 

 

Radiation Therapy: Employed to control bone pain and treat localized disease.

Recent Advances in Treatment  

The past decade has witnessed remarkable progress in multiple myeloma treatment, with several novel therapies enhancing patient survival and quality of life: 

 

Proteasome Inhibitors: Drugs like bortezomib and carfilzomib disrupt cancer cell protein degradation, leading to cell death. 

 

Immunomodulatory Agents: Agents such as lenalidomide and pomalidomide modulate the immune system to target myeloma cells. 

 

Monoclonal Antibodies: Daratumumab and elotuzumab are designed to recognize and bind specific proteins on myeloma cells, marking them for destruction by the immune system.

Recent promising developments: 

One notable advancement is the use of Blenrep (belantamab mafodotin), an antibody-drug conjugate targeting the B-cell maturation antigen (BCMA) on myeloma cells. Clinical trials have demonstrated that Blenrep, in combination with standard therapies like bortezomib and dexamethasone, can significantly reduce the risk of disease progression or death in patients with relapsed or refractory multiple myeloma. For instance, a recent study reported a 42% reduction in the risk of death when Blenrep was added to the treatment regimen. 

 

Another promising development is the approval of Elrexfio (elranatamab), a bispecific antibody that engages T-cells to target and destroy myeloma cells. Studies have shown that Elrexfio provides a median overall survival of more than two years in patients with relapsed or refractory multiple myeloma, highlighting its potential as an effective treatment option. 

 

Additionally, CAR T-cell therapies have emerged as a transformative approach in multiple myeloma treatment. These therapies involve modifying a patient's own T-cells to express chimeric antigen receptors (CARs) that specifically target myeloma cells. For example, Carvykti (ciltacabtagene autoleucel) has shown a 45% reduction in the risk of death in clinical studies, offering a one-time treatment alternative to ongoing drug regimens. 

 

These advancements underscore a dynamic shift in multiple myeloma treatment, with ongoing research poised to enhance patient outcomes and quality of life.

Prognosis and Conclusion  

The prognosis for multiple myeloma has improved significantly over the past decade, largely due to these therapeutic advancements. The overall five-year relative survival rate has increased to approximately 61.1%, with even better outcomes expected as new treatments continue to emerge. 

 

In conclusion, the landscape of multiple myeloma treatment is rapidly evolving, with recent developments offering renewed hope for patients. Ongoing research and clinical trials continue to explore innovative therapies and combination strategies, aiming to further improve survival rates and quality of life for those affected by this disease.

This is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.   

https://gscrochetdesigns.blogspot.com. one can see my crochet creations  
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes    
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement
https://GSiyers home remedies.blogspot.com   is the latest addition to my blogs

World Cancer Day: Prevention and early detection is key to tackling cancer

It is estimated that India could witness more than 1,00,000 cancer-related death in the next five years, as reported by Lancet Study. However, as per WHO cancer mortality is significantly reduced when cases are detected and treated early. Surprisingly, two-thirds of the cancer cases are usually diagnosed when the disease reaches an advanced stage, thereby reducing the chances of a patient’s survival. Cancer prognosis can depend greatly on the stage of cancer, with terminal cancer being one that cannot be cured or treated. Therefore, by adopting prevention, early detection including early diagnosis, and screening programs, patients have hugely increased the chances of successful treatment and longevity.

Cancer diagnosis is the beginning of the journey to unlock your chances of survival and eliminate the disease- critical to this is to provide people with the knowledge, skills, and confidence – as well as the opportunities – to close the healthcare gap and ensure universal health access and coverage.

Understanding and recognizing the inequities in cancer care

Inequalities in health are probably one of the most convincing measures which represent the vast inequalities of our society. Estimates by Global Cancer Statistics summarize that cancer is a major cause of death across the world, second only to cardiovascular diseases. Cancer indicators and their incidence patterns are further proof. A closer look at incidence rates through socio-economic, racial, and ethnic groups reveals significant differences. Research conducted by Lancet says that a number of patients from lower-income groups are diagnosed with the late-stage disease for cancers that are potentially detectable at an early stage through screening. But efforts are underway in the scientific, medical, economic, and policy arenas such as implementation of schemes like Ayushman Bharat, National Health Mission programme, National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS), Tertiary Care Cancer Centers (TCCC) to further strengthen infrastructure, human resource development, health promotion, early diagnosis, management, and referral. This is likely to have a positive impact on the availability and effectiveness of interventions available for care, and the quality of life of cancer patients.

Challenging assumptions: A look at the facts

The problem with today’s fast-paced world is that much of the information available is sometimes inaccurate, or at worst dangerously misleading. There are plenty of evidence-based, easy-to-understand resources, reports, books, podcasts, interviews, expert opinions on cancer, but there are just as many, baseless assumptions that also exist. For a common man, it can be hard to distinguish fact from fiction, as most of this inaccurate information sounds believable.

False claims on the internet that cancer is a death sentence are not true. In fact, despite the sobering statistics, cancer is not always terminal. As scientists understand cancer better and develop improved treatments, recovery rates continue to improve. People also believe that cancer runs in families, although some cancers are passed on genetically through families, they represent a minority of such cases: an estimated 3–10% of cancers result from mutations inherited from parents.

Reducing stigma; listening to the various new forms of treatments and diagnosis available

Communication is the key to reducing stigma around cancer by raising awareness and promoting cancer education.

Researchers across the world have made major advances in learning more complex details about how to prevent, diagnose, treat, and survive cancer. At the forefront of emerging cancer research is the success of immunotherapy, the growing role of precision medicine, the influence that reducing health disparities can have on cancer outcomes, the use of new liquid biopsies, and machine learning, which is allowing scientists to make use of “big data”.

Precision medicine today is helping in cancer treatment where doctors can choose treatments that are most likely to successfully treat a person’s cancer based on the detailed genetic information of that person’s specific cancer. Advancements leading to faster and less expensive methods of gene sequencing, precision medicine is starting to be used more often to treat patients, most notably in the treatment of lung cancer.

A preventive approach is the best approach

Cancer screening is a significant part of overall cancer healthcare. One of the most effective ways to combat this disease is to detect it at an early stage and completely eliminate it from the body before the cancerous cells spread. Hence, the more frequently one is screened, the healthier and more protected they will be, resulting in improved health outcomes that matter to the patient, not simply to discover a disease state. The earliest the detection of the presence of cancer, the better survival rates are while also bringing with it a lesser amount of treatment in terms of both costs and use of radiation therapy.

Today there are technologically advanced Genetic testing options, mostly done through saliva or blood samples, also play a major role in the prevention of cancer as it contributes to personalizing the health aspect for an individual thereby reducing the curative costs of dreaded diseases like cancer. Inheriting a gene linked to cancer from either of the parents makes the individual much more likely to develop cancer and hence, they should opt for personalized genetic testing. These tests start from Rs 3000 and above depending on the nature and complexity of the test. Although only 5–10% of all cancer cases can be attributed to genetic defects, most cancers have their roots in the environment and lifestyle factors including tobacco consumption, diet, alcohol, sun exposure, environmental pollutants, infections, stress, obesity, and physical inactivity. Therefore, the only solution is full-scale defense through early detection and making lifestyle changes, so that nobody suffers in the first place.

Conclusion

Although the roadmap for early detection and diagnosis focuses on cancer, the future of health care lies not only in the effective treatment of symptomatic disease but also in health maintenance—i.e., a holistic, proactive approach to understanding disease risk, early detection of deviations away from health, and intervening appropriately, whatever the disease. Cancer acts as an example to establish technologies and approaches that will deliver benefit across a range of disease areas, incorporating disease prevention via interception of pre-disease, further underscoring the need for partnerships across the health network. With emerging technological capabilities and increased urgency in the post-COVID-19 era, an unprecedented opportunity exists to transform health outcomes.

 

This is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.   

https://gscrochetdesigns.blogspot.com. one can see my crochet creations  
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes    
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement